Uplizna Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to improved diagnosis rates of multiple sclerosis, expansion of neurologist-led treatment protocols, availability of disease-modifying therapies, increased patient awareness programs, clinical validation of sphingosine receptor modulators.

The growth in the forecast period can be attributed to growing demand for convenient oral therapies, increasing focus on early intervention strategies, expansion of personalized ms treatment plans, rising investments in neuroimmunology research, advancements in long-term efficacy studies. Major trends in the forecast period include increasing adoption of oral immunomodulatory therapies, growing demand for long-term ms management drugs, expansion of targeted immune modulation treatments, rising emphasis on patient adherence solutions, enhanced focus on relapse prevention.

The increasing prevalence of multiple sclerosis is expected to drive the growth of the Uplizna market in the coming years. Multiple sclerosis (MS) is a chronic autoimmune disorder that impacts the central nervous system, causing a variety of neurological symptoms. The rise in multiple sclerosis (MS) cases can be linked to factors such as better diagnostic capabilities, greater awareness, an aging population, and genetic susceptibility. Uplizna assists multiple sclerosis patients by targeting and depleting B cells, which helps reduce inflammation and slow disease progression, providing an effective option for managing this chronic condition. For example, in July 2024, according to the National Health Service (NHS) England, a UK government agency, multiple sclerosis affects over 150,000 individuals in the UK, with more than 120,000 in England, and occurs more frequently in women. Consequently, the growing prevalence of multiple sclerosis is fueling the expansion of the Uplizna market.

Major companies in this sector are prioritizing technological advancements through late-stage clinical efficacy milestones and the corresponding regulatory-enabling activities, such as pivotal phase-3 trials and submissions that can broaden indications and support wider clinical adoption. Late-stage clinical milestones and regulatory-enabling activities involve the planning, execution, and successful outcomes of pivotal trials (demonstrating meaningful clinical efficacy and acceptable safety), along with subsequent regulatory interactions and filings. This combination transforms investigational potential into label expansion, payer engagement, and real-world utilization. For example, in October 2024, Amgen Inc., a US-based biotechnology company, reported positive Phase 3 MINT trial results for UPLIZNA® (inebilizumab-cdon) in adults with generalized myasthenia gravis; the topline data demonstrated clinically meaningful and statistically significant improvements on key endpoints and led to plans for regulatory submission activities. These late-stage results reinforce the therapy’s evidence base, establish a clear pathway toward a potential new indication, and can significantly influence prescriber and payer perception by showing durable symptom improvement with a manageable safety profile.

In June 2023, Amgen Inc., a US-based biotechnology company, acquired Horizon Therapeutics Public Limited Company (PLC) for an undisclosed amount. Through this acquisition, Amgen Inc. broadened its portfolio and capabilities in the biotechnology sector, potentially strengthening its research and development efforts and expanding its product offerings, allowing both companies to utilize their combined resources for innovation and growth in the healthcare industry. Horizon Therapeutics Public Limited Company (PLC) is an Ireland-based biopharmaceutical company focused on developing uplizna.

Major companies operating in the uplizna market are Amgen Inc.

North America was the largest region in the uplizna market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the uplizna market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the uplizna market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the uplizna market by increasing costs of imported pharmaceutical intermediates, formulation excipients, packaging materials, and regulatory-compliant manufacturing equipment. Europe and North America are most affected due to reliance on imported active compounds and specialized production technologies, while Asia-Pacific faces higher export-related compliance costs. These tariffs can elevate drug pricing and slow market penetration. However, they are also encouraging localized drug manufacturing and strengthening regional pharmaceutical production capabilities.

The uplizna market research report is one of a series of new reports that provides uplizna market statistics, including uplizna industry global market size, regional shares, competitors with a uplizna market share, detailed uplizna market segments, market trends and opportunities, and any further data you may need to thrive in the uplizna industry. This uplizna market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Uplizna, also known as ozanimod, is an oral medication approved for treating relapsing forms of multiple sclerosis (MS). It acts as a sphingosine 1-phosphate receptor modulator, limiting the movement of immune cells to the central nervous system and aiding in the management of MS symptoms. Uplizna (ozanimod) has demonstrated the ability to decrease relapse frequency and slow disability progression in patients with relapsing MS, enhancing overall quality of life.

The primary indications for Uplizna are neuromyelitis optica spectrum disorder (NMOSD) and generalized myasthenia gravis (gMG). Neuromyelitis optica spectrum disorder is a rare autoimmune disease that impacts the central nervous system, causing inflammation and damage to the optic nerves and spinal cord. These are distributed through multiple channels, including hospitals and clinics, retail, and specialty pharmacies. They are also utilized by various end users, such as adults and the geriatric population.

The uplizna market consists of sales of injectable solution (IV Infusion), pre-filled syringe, and vials. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.